BCM
CYT

Bridgeway Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Bridgeway Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32,800
Closed -$99.7K – 1397
2023
Q4 		$99.7K Buy
+32,800
New +$99.5K ﹤0.01% 1241
2023
Q2 		– Sell
-69,584
Closed -$127K – 1466
2023
Q1 		$127K Sell
69,584
-50,000
-42% -$81.2K ﹤0.01% 1192
2022
Q4 		$197K Hold
119,584
– – 0.01% 1095
2022
Q3 		$230K Buy
119,584
+50,000
+72% +$130K 0.01% 1106
2022
Q2 		$208K Buy
+69,584
New +$178K ﹤0.01% 1084

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Bridgeway Capital Management's CYT Position: Q1 2024 in Review

Bridgeway Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 32,800 shares — an estimated $99.7K sold.

Bridgeway Capital Management first reported a position in CYT in Q2 2022 and held it in 5 quarters. The position peaked at $230K in Q3 2022. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Bridgeway Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 32,800 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $99.7K.
  • Bridgeway Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Bridgeway Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $230K in Q3 2022.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bridgeway Capital Management's 13F filing for Q1 2024, filed 15 May 2024.